Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

112.09 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
61 62 Next >
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
By Julian Richard, Benzinga 
Via TheNewswire.com
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? 
Via News Direct
Gilead's Flagship CAR T-cell Therapy Shows Improved Overall Survival In Pretreated Lymphoma Patients
Via Benzinga
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Gilead Exercises First License Option Under Agreement With Nurix Therapeutics
Via Benzinga
Gilead Sciences Unusual Options Activity
Via Benzinga
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Successful Autologous Cell-Based Therapies 
Via Benzinga
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
With the COVID pandemic still ongoing, having claimed  more than 6.8 million lives from about 758 million cases and crippling the global economy, there are several reasons why drug research and... 
Via Benzinga
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
From Gilead Sciences, Inc.
Via Business Wire
A Look Into Gilead Sciences' Debt
Via Benzinga
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
Analyst Expectations for Gilead Sciences's Future
Via Benzinga
3 Stocks to Buy Right Now That Are Cash Cows
If cash is king, these three stocks should wear crowns. 
Via The Motley Fool
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines
Under Joe Biden's signature Inflation Reduction Act, drugmakers for twenty-seven drugs will be penalized for charging prices that rise faster than inflation for people with disabilities or the elderly... 
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Why Shares of MacroGenics Jumped Thursday
The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy. 
Via The Motley Fool
If You Invested $100 In This Stock 20 Years Ago, You Would Have $2,100 Today
Via Benzinga
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? 
Via News Direct
Topics Economy
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
2 Healthcare Stocks That Could Help Set You Up for Life
Even seemingly boring businesses can deliver solid returns over long periods. 
Via The Motley Fool
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. 
Via Benzinga
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD. 
Via Talk Markets
7 Cash-Rich Companies to Invest in During Economic Uncertainty
Although they’re not necessarily the most exciting enterprises, these cash-rich stocks should keep your portfolio upright. 
Via InvestorPlace
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows
Via Benzinga
Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
From Gilead Sciences, Inc.
Via Business Wire
Kite Completes Acquisition of Tmunity
From Gilead Sciences, Inc.
Via Business Wire
This Recession-Proof Company Has a Best-in-Class Dividend
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group. 
Via The Motley Fool
Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback